Eugenol inhibits non-small cell lung cancer by repressing expression of NF-κB-regulated TRIM59

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Eugenol exhibits anti-tumor properties against non-small cell lung cancer (NSCLC) in vitro.
• The in vivo therapeutic potential and molecular mechanisms of eugenol in NSCLC remain to be fully elucidated.

Purpose of the Study:

• To investigate the in vivo therapeutic effect of eugenol in NSCLC.
• To elucidate the molecular mechanism underlying eugenol's anti-tumor activity, focusing on the NF-κB-TRIM59 pathway.

Main Methods:

• Quantification of TRIM59 and p65 expression using real-time polymerase chain reaction.
• Establishment of a xenograft tumor model in mice to monitor tumor progression and overall survival (Kaplan-Meier analysis).
• Western blot analysis for protein levels, chromatin immunoprecipitation assay for DNA binding, and luciferase reporter assay for regulatory effects.

Main Results:

• Both TRIM59 and p65 were found to be upregulated in NSCLC tissues.
• Eugenol treatment significantly inhibited tumor progression and prolonged survival in xenograft models.
• Eugenol suppressed p65 expression, leading to decreased TRIM59 expression; TRIM59 deficiency mimicked eugenol's effects, while its overexpression abolished them.

Conclusions:

• Eugenol inhibits NSCLC progression and improves survival by repressing the NF-κB-TRIM59 pathway.
• TRIM59 plays a crucial role in mediating the anti-tumor effects of eugenol in NSCLC.
• Eugenol represents a potential therapeutic agent for NSCLC, acting through modulation of the NF-κB-TRIM59 signaling axis.